Becton, Dickinson and Company (BDX) has been attracting significant interest, both from investors and financial institutions. The company's shares have been bought and sold by various notable wealth management and retirement funds, signifying considerable movement and interaction with their stock. With
RBC Capital initiating sector perform coverage and
Royal Bank Of Canada's shift to a hold rating, the financial consensus around Becton Dickinson seems variable. The company has also made significant strides in the genomics sector with the 1,000th placement of BD Rhapsody, marked as a new innovation. Becton Dickinson's financial outlook for 2025 has been a topic of consideration with earnings being expected to decline for Q3, albeit excitement around strong EPS growth in Q2. The news of Becton Dickinson entering a merger with
Waters Corp, worth $17.5 billion, and securing a significant credit facility, were key business points of discussion. However, ensuing investor sentiment remains mixed due to challenges such as global research funding cuts and share performance over the last three years causing losses.
Becton Dickinson and BDX News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Sat, 27 Sep 2025 08:54:01 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor 4
